CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 116 filers reported holding CLOVIS ONCOLOGY INC in Q3 2013. The put-call ratio across all filers is 1.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $1,759,000 | -46.8% | 48,791 | -48.0% | 0.05% | -30.8% |
| Q4 2015 | $3,304,000 | +70.0% | 93,893 | +344.0% | 0.08% | +27.9% |
| Q3 2015 | $1,944,000 | -8.9% | 21,145 | -39.8% | 0.06% | +27.1% |
| Q3 2013 | $2,134,000 | -54.1% | 35,115 | -49.4% | 0.05% | -61.9% |
| Q2 2013 | $4,648,000 | – | 69,393 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |